A Powerful and Unique Tool for the Anti-VEGF Market

The market for treatments that target vascular endothelial growth factor (VEGF), a protein that can lead to vision problems when produced in excessive amounts, is highly competitive due to the rising prevalence of ophthalmic conditions and/or a large number of new entrants to the market. This isn’t surprising, given the demand for anti-VEGF agents: The global anti-VEGF market was valued at $12.36 billion in 2021 and is expected to reach $13.54 billion by 2030.

VEGF encourages the development of new blood vessels and promotes vascular permeability. However, when produced in excess inside an eye, VEGF can also cause abnormal blood vessels to form inside the eye and cause them to leak. This leakage can lead to retinal edema and may contribute to conditions such as neovascular age-related macular degeneration, diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. Anti-VEGF medications block VEGF, impeding the growth of abnormal blood vessels in a way that slows down vision loss and can, in many cases, improve a patient’s eyesight.

Currently, the U.S. Food and Drug Administration has approved four anti-VEGF agents and has also recently approved two biosimilar anti-VEGF agents. Because multiple anti-VEGF brands are now available in the U.S., retinal physicians have many options for treating their patients. The choice of therapeutic agent can be influenced by multiple factors, including each patient’s specific needs and circumstances. Ultimately, the goal is to maximize visual outcomes while partnering and engaging with patients. 

In light of these factors, which might influence utilization, manufacturers of anti-VEGF therapies have a crucial need to monitor market uptake and track their brand’s performance to guide sales and marketing strategies. Electronic health record-based registries can be particularly helpful in providing real-world data (RWD) and insights about these clinician-administered treatments.

Power of the IRIS Registry

Verana Health’s Qdata^Ⓡ Anti-VEGF Market Tracker – the first Verana Health market tracking Data-as-a-Service (DaaS) product – leverages RWD from the American Academy of Ophthalmology IRIS® Registry (Intelligent Research in Sight) to actively and accurately track usage of anti-VEGF therapies. This de-identified dataset generates insights by brand, geography, patient demographics, clinician subspecialty, and is available to life sciences companies in the form of customizable market dashboards or via direct data access. 

The IRIS Registry includes data on more than 2.2 million patients who received anti-VEGF injections as of 2023. Verana Health’s Qdata Anti-VEGF Market Tracker offers de-identified, curated IRIS Registry data. In 2022 alone, this includes:

• More than 4.8 million anti-VEGF injections
• More than 850,000 de-identified patients
• More than 2,300 ophthalmologists
• Data across six key retinal conditions
• 8 brands and growing as new ones are FDA-approved

Fresh data, deep insights

The Qdata Anti-VEGF Market Tracker offers Verana Health customers perspectives on the anti-VEGF market by providing granular market segmentation down to the brand level that cannot be found on this scale anywhere else.

The Qdata Anti-VEGF Market Tracker offers Verana Health customers perspectives on the anti-VEGF market by providing granular market segmentation down to the brand level that cannot be found on this scale anywhere else. Unlike some claims data, which is derived from billing codes, the Qdata Anti-VEGF Market Tracker includes the specific brand of anti-VEGF therapy used. This brand granularity will be particularly important because of several biosimilar anti-VEGF agents launching in the U.S. Market. In addition, RWD from our market tracker is made available within a month, whereas claims data can take up to three months to be accessible. It also includes brand-level granularity which claims is not always able to do. Timely and brand level data helps life sciences companies identify market trends earlier, and can help better inform commercial planning and sales forecasting. 

Not only can Verana Health customers access data through a highly intuitive dashboard, they can also download data on demand via Amazon’s AWS Data Exchange to conduct deep analyses of data. The Qdata Anti-VEGF Market Tracker provides insights for many different customer needs ranging from a deep-dive into their own product, to comprehensive information on the broader anti-VEGF market. Additionally, Verana Health’s Quantitative Sciences team can analyze datasets to help provide customers with custom insights into the anti-VEGF market. 

The goal of the Qdata Anti-VEGF Market Tracker is to actively and accurately track real-world usage of anti-VEGF therapies in patients with retinal conditions, and provide customers access to data that can help improve their commercial strategies.